OptiNose, Inc. (OPTN) Q3 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlighted several concerns: conservative revenue guidance, challenges with insurance coverage, and unclear management responses in the Q&A. Financial performance showed modest growth, but guidance was lowered, and no shareholder returns were announced. Despite positive revenue per prescription, the lack of concrete guidance and competitive pressures in the market suggest a negative sentiment. These factors, combined with economic uncertainties and the absence of a market cap, lead to a prediction of a stock price decrease in the range of -2% to -8% over the next two weeks.
Key Financial Performance
XHANCE net revenue (Q3 2024) $20.4 million, a 3% increase compared to $19.8 million in Q3 2023. The increase is attributed to inventory growth in the channel and the addition of new dispensing pharmacies.
Average net revenue per prescription (Q3 2024) $320, a 36% increase compared to $236 in Q3 2023. The increase is driven by a favorable business mix from changes to the co-pay support program and channel inventory build.
XHANCE net revenue (Year-to-date through September 2024) $55.8 million, a 9% increase compared to $51.1 million in the prior year period.
Average net revenue per prescription (Year-to-date through September 2024) $285, a 45% increase compared to $197 in the prior year period. The increase is primarily due to changes in the co-pay assistance program.
SG&A plus R&D expenses (Q3 2024) $20.4 million, an increase of approximately $1 million compared to $19.3 million in Q3 2023, attributed to promotional efforts supporting the chronic sinusitis launch.
SG&A plus R&D expenses (Year-to-date through September 2024) $67.2 million, an increase of approximately $2 million compared to $64.9 million in the prior year period, also due to promotional efforts.
Full-year 2024 XHANCE net revenue guidance $75 million to $79 million, down from previous expectations of $85 million to $90 million, reflecting a delayed inflection in prescription growth.
Average net revenue per prescription (Full-year 2024) Expected to be approximately $270, a 29% increase compared to $209 in full-year 2023, driven by revisions to the co-pay assistance program.
Operating expenses (Full-year 2024) Guidance of $90 million to $93 million, down from previous expectations of $95 million to $101 million, due to lower-than-projected variable product expenses and payroll savings.
Operating Highlights
XHANCE Net Revenue: OptiNose reported $20.4 million of XHANCE net revenue for Q3 2024, a 3% increase from $19.8 million in Q3 2023.
Average Net Revenue per Prescription: The average net revenue per prescription for Q3 2024 was $320, a 36% increase from $236 in Q3 2023.
Peak Revenue Potential: OptiNose believes peak annual net revenue for XHANCE could exceed $300 million, driven by specialty-focused efforts.
New Indication Coverage: XHANCE was added to Express Scripts' national formularies, improving access for patients with chronic sinusitis.
Market Expansion: OptiNose is exploring ways to enter the primary care market to access a significant incremental revenue opportunity.
New Prescriber Engagement: The company is focusing on increasing the number of prescribers new to XHANCE, particularly in the chronic sinusitis market.
Sales Force Execution: The sales force is concentrating on efficacy-focused discussions and targeting top chronic sinusitis potential HCPs.
Hub Services Optimization: Improvements in hub services and pharmacy network are being implemented to enhance prescription fulfillment.
Financial Guidance Adjustment: OptiNose revised its 2024 revenue guidance for XHANCE to $75 million to $79 million, down from $85 million to $90 million.
Cost Structure Management: The company is continuously monitoring its spending and evaluating the cost structure to ensure it aligns with growth.
Risk or Challenges
Revenue Expectations: OptiNose reported $20.4 million of XHANCE net revenue for Q3 2024, which was below expectations. The company has reduced its revenue guidance for full-year 2024 to a range of $75 million to $79 million, down from $85 million to $90 million, indicating a slower than anticipated uptake.
Insurance Coverage Challenges: Approximately 70% of lives are in insurance plans that cover XHANCE, but about 50% of commercial covered lives are subject to prior authorizations, which complicates prescription fulfillment and may deter prescribers.
Sales Execution: The sales force execution has been a focus area, with the need for improved messaging and frequency of calls to prescribers. The company noted that it could take 10 to 12 calls for new prescribers to fully understand and adopt XHANCE.
Supply Chain and Fulfillment: The transition to a new hub services platform for prescription fulfillment has required more time and effort to optimize than initially anticipated, impacting the overall efficiency of prescription fulfillment.
Market Competition and Adoption: The company faces competitive pressures in the chronic sinusitis market, and the initial launch has been slower than expected, necessitating ongoing efforts to educate prescribers about the benefits of XHANCE.
Economic Factors: The overall economic environment and healthcare policies may impact the adoption rates and insurance coverage for XHANCE, influencing the company's revenue projections.
Guidance & Outlook
Peak Annual Net Revenue: OptiNose believes peak annual net revenue for XHANCE will exceed $300 million, driven by specialty-focused efforts.
Chronic Sinusitis Market Opportunity: The company sees a significant long-term opportunity in the chronic sinusitis market, with an estimated 10 million diagnoses per year.
Sales Force Strategy: In 2024, OptiNose will commercialize XHANCE without changing the size of its sales force, focusing on enhanced targeting and messaging.
Insurance Coverage Improvements: OptiNose aims to improve insurance coverage for XHANCE, including recent additions to Express Scripts' national formularies.
Primary Care Market Exploration: The company is exploring ways to enter the primary care market to capture additional revenue opportunities.
2024 Revenue Guidance: OptiNose revised its 2024 XHANCE net revenue guidance to $75 million to $79 million, down from $85 million to $90 million.
Average Net Revenue per Prescription: The company expects average net revenues per prescription to be approximately $270 for full-year 2024, a 29% increase from 2023.
Operating Expenses Guidance: Operating expense guidance for 2024 is now $90 million to $93 million, down from $95 million to $101 million.
Cash Flow Outlook: OptiNose believes existing cash and cash equivalents will be sufficient to fund operations for at least the next 12 months.
Shareholder Return Plan
XHANCE net revenue guidance for full-year 2024: OptiNose now expects XHANCE net revenue to be between $75 million to $79 million, down from previous expectations of $85 million to $90 million.
Average net revenue per prescription: The average net revenue per prescription for XHANCE is expected to be approximately $270 for the full-year of 2024, which represents an increase of approximately 29% compared to $209 for the full-year of 2023.
Operating expenses guidance for full-year 2024: OptiNose's full-year 2024 operating expense guidance is now $90 million to $93 million, down from previous expectations of $95 million to $101 million.
Stock-based compensation: Approximately $6 million of the operating expenses is expected to be stock-based compensation.
Cash and cash equivalents: OptiNose believes its existing cash and cash equivalents will be sufficient to fund operations and debt service obligations for at least the next 12 months.
Key Q&A
Earnings Word Cloud
OPTN Transcript
The earnings call highlighted several concerns: conservative revenue guidance, challenges with insurance coverage, and unclear management responses in the Q&A. Financial performance showed modest growth, but guidance was lowered, and no shareholder returns were announced. Despite positive revenue per prescription, the lack of concrete guidance and competitive pressures in the market suggest a negative sentiment. These factors, combined with economic uncertainties and the absence of a market cap, lead to a prediction of a stock price decrease in the range of -2% to -8% over the next two weeks.
The earnings call summary indicates strong revenue growth and an increase in average net revenue per prescription, suggesting positive financial performance. Despite concerns about competitive pressures and supply chain challenges, the company expects significant revenue growth and a clear path to profitability by 2025. The Q&A section reveals optimism about revenue targets and potential upside in net revenue per prescription. The lack of clarity in some management responses slightly tempers the positive outlook, but overall, the sentiment is favorable, indicating a likely positive stock price movement.
The company's financial performance shows a decrease in net revenue and a high dependency on FDA approval for future growth. The challenges in payer dynamics and reimbursement, along with market competition, add uncertainties. Although operating expenses have been reduced, the company avoided providing specific guidance, which may concern investors. The Q&A section did not alleviate these concerns, as management was unclear about future expectations. Overall, the sentiment is negative due to the reliance on uncertain factors like FDA approval and market adoption.
OPTN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
